Background: Ethnic variations have been described in medical conditions, such as hypertension, diabetes, and multiple sclerosis. Whether ethnicity plays a role in Parkinson's disease (PD), particularly with regard to non-motor symptoms (NMS), remains unclear. Existing literature is diverse, controversial, and inadequately documented. This review aims to analyse and report the currently available literature on NMS, specifically in Asian PD patients. Summary: We conducted a literature review using PubMed, searching for articles and currently available publications that reference and assess NMS in PD patients living in Asia using the validated NMS Questionnaire (NMS Quest) and NMS Scale (NMSS). In total, 24 articles were included: 12 using the NMS Quest and 12 using the NMSS. Symptoms of constipation, memory impairment, and nocturia were the most frequently self-reported symptoms (NMS Quest) in selected Asian populations, while symptoms within the domains sleep/fatigue, attention/memory, and mood/apathy were most prevalent when applying the health-professional completed NMSS. Key Messages: NMS are generally prevalent and highly burdensome within selected Asian PD populations living in countries included in this review. Our review suggests that NMS-driven phenotypic heterogeneity is present in Asian patients, and compared to Western PD populations there might be variations in assessed NMS.

Keywords:
Non-motor symptoms, Parkinson, Asia, Ethnicity
1.
Kalia LV, Lang AE: Parkinson's disease. Lancet 2015;386:896-912.
2.
Chaudhuri KR, Hu MT, Brooks DJ: Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. Mov Disord 2000;15:18-23.
3.
Chen W, Xu ZM, Wang G, Chen SD: Non-motor symptoms of Parkinson's disease in China: a review of the literature. Parkinsonism Relat Disord 2012;18:446-452.
4.
Parkinson J: An essay on the shaking palsy. Lon Med Phys J 1817:38.
5.
Titova N, Padmakumar C, Lewis SJ, Chaudhuri KR: Parkinson's: a syndrome rather than a disease? J Neural Transm (Vienna) 2016, Epub ahead of print.
6.
Zis P, Erro R, Walton CC, Sauerbier A, Chaudhuri KR: The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis 2015;1:15013.
7.
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR: The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Dis 2011;26:399-406.
8.
Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA: Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease. Expert Opin Drug Metab Toxicol 2016;12:433-448.
9.
Marmot M, Wilkinson R: Social determinants of health. Expert Opinion Drug Metab Toxicol 2016;12:433-448.
10.
Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW: International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-923.
11.
Rana AQ, Athar A, Owlia A, Siddiqui I, Awan N, Fattah A, Rana MA: Impact of ethnicity on non-motor symptoms of Parkinson's disease. J Parkinsons Dis 2012;2:281-285.
12.
Cubo E, Doumbe J, Martinez-Martin P, Rodriguez-Blazquez C, Kuate C, Mariscal N, Lopez I, Noubissi G, Mapoure YN, Jon JL, Mbahe S, Tchaleu B, Catalan MJ: Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian cohorts. J Neurol Sci 2014;336:122-126.
13.
Sauerbier A, Jitkritsadakul O, Bhidayasiri R, Al-Hashel JY, Kamel WA, Kilany A, Farombi T, Martinez-Martin P, Brown R, Parry M, Martin A, Inniss R, Perkins L, Trivedi D, Klingelhoefer L, Rizos A, Dimitrov N, Zis P, Chaudhuri KR: Non-motor symptoms profiles of different ethnic groups with Parkinson's disease: a cross sectional study comparing the UK, Thailand, Nigeria and Kuwait. Mov Disord 2015;30:2097.
14.
Sauerbier A, Jitkritsadakul O, Bhidayasiri R, Kumar H, Martinez-Martin P, Banerjee R, Kulsum M, Rizos A, Carr H, Qamar MA, Perkins L, Chiwera T, Trivedi D, Martin A, Parry M, Brown R, Al-Hashel J, Kamel W, Kilany A, Lim S, Tan A, Bhattacharyya J, Walker R, Chaudhuri KR; On behalf of EUROPAR tMN-MPSGatNG: Non-motor symptoms profiles in UK white Caucasian and Asian as well as overseas Thai and East Indian patients with Parkinson's disease. Mov Disord 2016;31:829.
15.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
16.
Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH: The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007;22:1901-1911.
17.
Cheon SM, Ha MS, Park MJ, Kim JW: Nonmotor symptoms of Parkinson's disease: prevalence and awareness of patients and families. Parkinsonism Relat Disord 2008;14:286-290.
18.
Wang G, Wan Y, Cheng Q, Xiao Q, Wang Y, Zhang J, Ma JF, Wang XJ, Zhou HY, Chen SD: Malnutrition and associated factors in Chinese patients with Parkinson's disease: results from a pilot investigation. Parkinsonism Relat Disord 2010;16:119-123.
19.
Yu B, Xiao ZY, Li JZ, Yuan J, Liu YM: Study of an integrated non-motor symptoms questionnaire for Parkinson's disease. Chin Med J 2010;123:1436-1440.
20.
Zhou MZ, Gan J, Wei YR, Ren XY, Chen W, Liu ZG: The association between non-motor symptoms in Parkinson's disease and age at onset. Clin Neurol Neurosurg 2013;115:2103-2107.
21.
Gan J, Zhou M, Chen W, Liu Z: Non-motor symptoms in Chinese Parkinson's disease patients. J Clin Neurosci 2014;21:751-754.
22.
Vongvaivanich K, Nidhinandana S, Udommongkol C, Chairungsaris P, Chinvarun Y, Wongmek W, Suphakasem S, Suwantamee J, Sithinamsuwan P: Non-motor symptoms in Thai patients with Parkinson's disease studied at Phramongkutklao Hospital. J Med Assoc Thai 2014;97(suppl 2):S159-S167.
23.
Li DW, Gu Z, Wang C, Ma J, Tang BS, Chen SD, Chan P: Non-motor symptoms in Chinese Parkinson's disease patients with and without LRRK2 G2385R and R1628P variants. J Neural Transm (Vienna) 2015;122:661-667.
24.
Zhang N, Liu W, Ye M, Cohen AD, Zhang Y: The heterogeneity of non-motor symptoms of Parkinson's disease. Neurol Sci 2015;36:577-584.
25.
Li HJ, Zhang MF, Chen MX, Hu AL, Li JB, Zhang B, Liu W: Validation of the nonmotor symptoms questionnaire for Parkinson's disease: results from a Chinese pilot study. Int J Neurosci 2015;125:929-935.
26.
Rukmini Mridula K, Borgohain R, Jabeen SA, Padmaja G, Bandaru VS, Ankathi P, Kanikannan MA, Ali Khan MS: Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: a case-control study. Iran J Neurol 2015;14:86-93.
27.
Sengul Y, Sengul HS, Sural MK, Bakim B, Forta H: A comparison between rate of nonmotor symptom development in essential tremor and Parkinson's disease. Acta Neurol Belg 2015;115:289-294.
28.
Liu WM, Lin RJ, Yu RL, Tai CH, Lin CH, Wu RM: The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan. Neuropsychiatr Dis Treat 2015;11:2865-2873.
29.
Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, Lee DH, Jeon BS: Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 2009;287:200-204.
30.
Kim HS, Cheon SM, Seo JW, Ryu HJ, Park KW, Kim JW: Nonmotor symptoms more closely related to Parkinson's disease: comparison with normal elderly. J Neurol Sci 2013;324:70-73.
31.
Kim SR, So HY, Choi E, Kang JH, Kim HY, Chung SJ: Influencing effect of non-motor symptom clusters on quality of life in Parkinson's disease. J Neurol Sci 2014;347:310-315.
32.
Krishnan S, Sarma G, Sarma S, Kishore A: Do nonmotor symptoms in Parkinson's disease differ from normal aging? Mov Disord 2011;26:2110-2113.
33.
Guo X, Song W, Chen K, Chen X, Zheng Z, Cao B, Huang R, Zhao B, Wu Y, Shang HF: Disease duration-related differences in non-motor symptoms: a study of 616 Chinese Parkinson's disease patients. J Neurol Sci 2013;330:32-37.
34.
Guo X, Song W, Chen K, Chen X, Zheng Z, Cao B, Huang R, Zhao B, Wu Y, Shang HF: Gender and onset age-related features of non-motor symptoms of patients with Parkinson's disease - a study from Southwest China. Parkinsonism Relat Disord 2013;19:961-965.
35.
Song W, Guo X, Chen K, Chen X, Cao B, Wei Q, Huang R, Zhao B, Wu Y, Shang HF: The impact of non-motor symptoms on the Health-Related Quality of Life of Parkinson's disease patients from Southwest China. Parkinsonism Relat Disord 2014;20:149-152.
36.
Ou R, Yang J, Cao B, Wei Q, Chen K, Chen X, Zhao B, Wu Y, Song W, Shang H: Progression of non-motor symptoms in Parkinson's disease among different age populations: a two-year follow-up study. J Neurol Sci 2016;360:72-77.
37.
Ou R, Song W, Wei Q, Chen K, Cao B, Hou Y, Zhao B, Shang H: Characteristics of nonmotor symptoms in progressive supranuclear palsy. Parkinsons Dis 2016;2016:9730319.
38.
Wu Y, Guo XY, Wei QQ, Ou RW, Song W, Cao B, Zhao B, Shang HF: Non-motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson's disease patients. Acta Neurol Scand 2016;133:330-337.
39.
Zhang S, Ou R, Chen X, Yang J, Zhao B, Yuan X, Wei Q, Cao B, Shang HF: Correlative factors of cognitive dysfunction in PD patients: a cross-sectional study from Southwest China. Neurol Res 2016;38:434-440.
40.
Yong MH, Allen JC Jr, Prakash KM, Tan EK: Differentiating non-motor symptoms in Parkinson's disease from controls and hemifacial spasm. PLos One 2013;8:e49596.
41.
Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G: MDS research criteria for prodromal Parkinson's disease. Mov Disord 2015;30:1600-1611.
42.
Jellinger KA: Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) 2015;122:1429-1440.
43.
Sauerbier A, Jenner P, Todorova A, Chaudhuri KR: Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord 2016;22(suppl 1):S41-S46.
44.
Sauerbier A, Qamar MA, Rajah T, Chaudhuri KR: New concepts in the pathogenesis and presentation of Parkinson's disease. Clin Med (Lond) 2016;16:365-370.
45.
Martinez-Martin P, Falup Pecurariu C, Odin P, van Hilten JJ, Antonini A, Rojo-Abuin JM, Borges V, Trenkwalder C, Aarsland D, Brooks DJ, Ray Chaudhuri K: Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. J Neurol 2012;259:1639-1647.
46.
Politis M, Wu K, Molloy S, G Bain P, Chaudhuri KR, Piccini P: Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010;25:1646-1651.
47.
Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, Antonini A, Brown RG, Martinez-Martin P: A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One 2013;8:e57221.
48.
Zhang L, Yan J, Xu Y, Long L, Zhu C, Chen X, Jiang Y, Yang L, Bian L, Wang Q: The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism. PLoS One 2011;6:e19333.
49.
Tsuboi Y, Yamada T, Chaudhuri KR, Martinez-Martin P, Schapira AH; Group TiPNM: Comparison of profile of no motor symptoms in Japense patients with PD with European patients and healthy controls. Extension of the NMSQuest study. Mov Disord 2006;21:S648.
50.
Maeda T, Shimo Y, Chiu SW, Yamaguchi T, Kashihara K, Tsuboi Y, Nomoto M, Hattori N, Watanabe H, Saiki H: Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers. Parkinsonism Relat Disord 2017;38:54-60.
51.
Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR: Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22:1623-1629.
52.
Das D, Biswas A, Roy A, Sauerbier A, Bhattacharyya KB: Cognitive impairment in idiopathic Parkinson's disease. Neurol India 2016;64:419-427.
53.
Crispo JA, Willis AW, Thibault DP, Fortin Y, Hays HD, McNair DS, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison DR, Krewski D: Associations between anticholinergic burden and adverse health outcomes in Parkinson disease. PLoS One 2016;11:e0150621.
54.
Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, Wadup L, Postuma RB: Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord 2012;18:54-58.
55.
Li H, Zhang M, Chen L, Zhang J, Pei Z, Hu A, Wang Q: Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson's disease. Mov Disord 2010;25:2740-2746.
56.
Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK: The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study. Eur J Neurol 2016;23:854-860.
57.
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD: The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-1649.
58.
Nataliya Titova PJ, Ray Chaudhuri K: The future of Parkinson's treatment - personalised and precision medicine. Eur Neurol Rev 2017;12:15-16.
59.
Zis P, Martinez-Martin P, Sauerbier A, Rizos A, Sharma JC, Worth PF, Sophia R, Silverdale M, Chaudhuri KR: Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes. Eur J Neurol 2015;22:1145-1150.
60.
Jaquet M, Rochat I, Moulin J, Cavin C, Bibiloni R: Impact of coffee consumption on the gut microbiota: a human volunteer study. Int J Food Microbiol 2009;130:117-121.
61.
Azmin S, Khairul Anuar AM, Tan HJ, Nafisah WY, Raymond AA, Hanita O, Shah SA, Norlinah MI: Nonmotor symptoms in a malaysian Parkinson's disease population. Parkinsons Dis 2014;2014:472157.
62.
Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
63.
Zhang H, Yin X, Ouyang Z, Chen J, Zhou S, Zhang C, Pan X, Wang S, Yang J, Feng Y, Yu P, Zhang Q: A prospective study of freezing of gait with early Parkinson disease in Chinese patients. Medicine (Baltimore) 2016;95:e4056.
64.
Congress EP, Lyons BP: Cultural differences in health beliefs: implications for social work practice in health care settings. Soc Work Health Care 1992;17:81-96.
65.
Zhang ZX, Chen H, Chen SD, Shao M, Sun SG, Qu QM, Zhang BR, Liu YM, Xu Q, Wan X, Li L, Wen HB, Chen X, Chen HB, Liu ZG, Wang J, Wang G: Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China. BMC Res Notes 2014;7:65.
66.
Chen W, Xiao Q, Shao M, Feng T, Liu WG, Luo XG, Chen XC, Xie AM, Liu CF, Liu ZG, Liu YM, Wang J, Chen SD: Prevalence of wearing-off and dyskinesia among the patients with Parkinson's disease on levodopa therapy: a multi-center registry survey in mainland China. Transl Neurodegener 2014;3:26.
67.
Chin Med Asso Neurology: Movement disorder and Parkinson disease. Treatment guideline of Parkinson disease. Chin J Neurol 2006;39:409-412.
68.
Lim SY, Tan ZK, Ngam PI, Lor TL, Mohamed H, Schee JP, Tan AK, Goh JY, Ooi E, Soh PC: Impulsive-compulsive behaviors are common in Asian Parkinson's disease patients: assessment using the QUIP. Parkinsonism Relat Disord 2011;17:761-764.
69.
Auyeung M, Tsoi TH, Tang WK, Cheung CM, Lee CN, Li R, Yeung E: Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist. Parkinsonism Relat Disord 2011;17:635-637.
70.
Guo YJ, Liao YC, Lin CH, Chang MH: Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan. PLoS One 2014;9:e107465.
71.
Bhidayasiri R, Hattori N, Jeon B, Chen RS, Lee MK, Bajwa JA, Mok VC, Zhang B, Syamsudin T, Tan LC, Jamora RD, Pisarnpong A, Poewe W: Asian perspectives on the recognition and management of levodopa ‘wearing-off' in Parkinson's disease. Expert Rev Neurother 2015;15:1285-1297.
72.
Peeraully T, Tan EK: Genetic variants in sporadic Parkinson's disease: East vs West. Parkinsonism Relat Disord 2012;18(suppl 1):S63-S65.
73.
Huang T, Shu Y, Cai YD: Genetic differences among ethnic groups. BMC Genomics 2015;16:1093.
74.
Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972-1977.
75.
Tan EK, Tong J, Fook-Chong S, Yih Y, Wong MC, Pavanni R, Zhao Y: Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 2007;64:1056-1058.
76.
Wu YR, Chen CM, Chao CY, Ro LS, Lyu RK, Chang KH, Lee-Chen GJ: Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 2007;78:977-979.
77.
Ziegler SG, Eblan MJ, Gutti U, Hruska KS, Stubblefield BK, Goker-Alpan O, LaMarca ME, Sidransky E: Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 2007;91:195-200.
78.
Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG: Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
79.
Huang CL, Wu-Chou YH, Lai SC, Chang HC, Yeh TH, Weng YH, Chen RS, Huang YZ, Lu CS: Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan. Eur J Neurol 2011;18:1227-1232.
80.
Hu FY, Xi J, Guo J, Yu LH, Liu L, He XH, Liu ZL, Zou XY, Xu YM: Association of the glucocerebrosidase N370S allele with Parkinson's disease in two separate Chinese Han populations of mainland China. Eur J Neurol 2010;17:1476-1478.
81.
Mao XY, Burgunder JM, Zhang ZJ, An XK, Zhang JH, Yang Y, Li T, Wang YC, Chang XL, Peng R: Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland China. Neurosci Lett 2010;469:256-259.
82.
Wang Y, Liu L, Xiong J, Zhang X, Chen Z, Yu L, Chen C, Huang J, Zhang Z, Mohmed AA, Lin Z, Xiong N, Wang T: Glucocerebrosidase L444P mutation confers genetic risk for Parkinson's disease in central China. Behav Brain Funct 2012;8:57.
83.
Zhang X, Bao QQ, Zhuang XS, Gan SR, Zhao D, Liu Y, Hu Q, Chen Y, Zhu F, Wang L, Wang N: Association of common variants in the glucocerebrosidase gene with high susceptibility to Parkinson's disease among Chinese. Chin J Physiol 2012;55:398-404.
84.
Chen J, Li W, Zhang T, Wang YJ, Jiang XJ, Xu ZQ: Glucocerebrosidase gene mutations associated with Parkinson's disease: a meta-analysis in a Chinese population. PLoS One 2014;9:e115747.
85.
Wang C, Cai Y, Gu Z, Ma J, Zheng Z, Tang BS, Xu Y, Zhou Y, Feng T, Wang T, Chen SD, Chan P: Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. Neurobiol Aging 2014;35:725.e721-e726.
86.
Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, Gasser T, Berg D: GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 2015;30:407-411.
87.
Pal G, Robertson E, O'Keefe J, Hall D: The neuropsychiatric and motor profile of GBA-associated Parkinson's disease: a review. Mov Disord Clin Pract 2016;3:4-8.
88.
Weinshilboum RM, Raymond FA: Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet 1977;29:125-135.
89.
Jeanjean AP, Laterre EC, Maloteaux JM: Neuroleptic binding to sigma receptors: possible involvement in neuroleptic-induced acute dystonia. Biol Psychiatry 1997;41:1010-1019.
90.
Boudikova B, Szumlanski C, Maidak B, Weinshilboum R: Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 1990;48:381-389.
91.
McLeod HL, Syvanen AC, Githang'a J, Indalo A, Ismail D, Dewar K, Ulmanen I, Sludden J: Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 1998;8:195-199.
92.
Klemetsdal B, Straume B, Giverhaug T, Aarbakke J: Low catechol-O-methyltransferase activity in a Saami population. Eur J Clin Pharmacol 1994;46:231-235.
93.
Kunugi H, Vallada HP, Sham PC, Hoda F, Arranz MJ, Li T, Nanko S, Murray RM, McGuffin P, Owen M, Gill M, Collier DA: Catechol-O-methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatr Genet 1997;7:97-101.
94.
Makoff AJ, Graham JM, Arranz MJ, Forsyth J, Li T, Aitchison KJ, Shaikh S, Grunewald RA: Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 2000;10:43-48.
95.
Kim HJ, Jeon B: How close are we to individualized medicine for Parkinson's disease? Expert Rev Neurother 2016;16:815-830.
96.
Pocock SJ, Elbourne DR: Randomized trials or observational tribulations? N Engl J Med 2000;342:1907-1909.
97.
Sauerbier A, Lenka A, Aries A, Pal PK: Nonmotor symptoms in Parkinson's disease: gender and ethnic differences. Int Rev Neurobiol 2017 (submitted).
98.
SauerbierA, Klingelhoefer L, Banerjee R, Diaconu S, Erro R, Farombi T, Gangadharan S, Macerollo A, Chahine L, Jitkritsadakul O, Biundo R, Grilo M, Dafsari H, Pagano G, Niccolini F, Titova N: A global survey of the use and linguistic translation of the NMSQuest and NMSScale: implications for non-motor studies in Parkinson's disease. Mov Disord 2017;32(suppl 2). http://www.mdsabstracts.org/abstract/a-global-survey-of-the-use-and-linguistic-translation-of-the-nmsquest-and-nmsscale-implications-for-non-motor-studies-in-parkinsons-disease/ (accessed June 29, 2017).
99.
Ohayon MM, O'Hara R, Vitiello MV: Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev 2012;16:283-295.
100.
Yu RL, Wu RM, Chan AY, Mok V, Wu YR, Tilley BC, Luo S, Wang L, LaPelle NR, Stebbins GT, Goetz CG: Cross-cultural differences of the non-motor symptoms studied by the traditional Chinese version of the International Parkinson and Movement Disorder Society - Unified Parkinson's Disease Rating Scale. Mov Disord Clin Pract 2017;4:68-77.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.